Search research articles
Contact Us
Filters
Showing results (311-320 of 537) with videos related to
Page
of 54
Sort By:
Annals of the Rheumatic Diseases
|
February 1, 2014
Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial
Christopher Ritchlin, Proton Rahman, Arthur Kavanaugh, et al.
BMC Rheumatology
|
February 3, 2024
Continuous improvement through differential trajectories of individual minimal disease activity criteria with guselkumab in active psoriatic arthritis: post hoc analysis of a phase 3, randomized, double-blind, placebo-controlled study
Laura C Coates, Proton Rahman, Philip J Mease, et al.
Nature Reviews. Disease Primers
|
January 8, 2021
Tendinopathy
Neal L Millar, Karin G Silbernagel, Kristian Thorborg, et al.
Rheumatology (Oxford, England)
|
October 18, 2015
Assessment of murine collagen-induced arthritis by longitudinal non-invasive duplexed molecular optical imaging
Hannah E Scales, Michelle Ierna, Karen M Smith, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
January 23, 2003
A novel anti-inflammatory role for simvastatin in inflammatory arthritis
Bernard P Leung, Naveed Sattar, Anne Crilly, et al.
Annals of the Rheumatic Diseases
|
February 21, 2014
Ustekinumab, an anti-IL-12/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, placebo-controlled PSUMMIT-1 and PSUMMIT-2 trials
Arthur Kavanaugh, Christopher Ritchlin, Proton Rahman, et al.
Arthritis Research & Therapy
|
May 4, 2019
Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data
A Deodhar, P J Mease, I B McInnes, et al.
Journal of Clinical Periodontology
|
August 2, 2013
Influence of periodontal disease, Porphyromonas gingivalis and cigarette smoking on systemic anti-citrullinated peptide antibody titres
David F Lappin, Danae Apatzidou, Anne-Marie Quirke, et al.
Annals of the Rheumatic Diseases
|
April 22, 2014
Clinical efficacy, radiographic and safety findings through 5 years of subcutaneous golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of a randomised, placebo-controlled trial (the GO-REVEAL study)
Arthur Kavanaugh, Iain B McInnes, Philip Mease, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy
|
August 21, 2017
MicroRNA29a Treatment Improves Early Tendon Injury
Ashlee E Watts, Neal L Millar, Josh Platt, et al.
Page
of 54
Search research articles
Search
Showing results (311-320 of 537) with videos related to
Sort By:
Page
of 54
Annals of the Rheumatic Diseases
|
February 1, 2014
Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial
Christopher Ritchlin, Proton Rahman, Arthur Kavanaugh, et al.
BMC Rheumatology
|
February 3, 2024
Continuous improvement through differential trajectories of individual minimal disease activity criteria with guselkumab in active psoriatic arthritis: post hoc analysis of a phase 3, randomized, double-blind, placebo-controlled study
Laura C Coates, Proton Rahman, Philip J Mease, et al.
Nature Reviews. Disease Primers
|
January 8, 2021
Tendinopathy
Neal L Millar, Karin G Silbernagel, Kristian Thorborg, et al.
Rheumatology (Oxford, England)
|
October 18, 2015
Assessment of murine collagen-induced arthritis by longitudinal non-invasive duplexed molecular optical imaging
Hannah E Scales, Michelle Ierna, Karen M Smith, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
January 23, 2003
A novel anti-inflammatory role for simvastatin in inflammatory arthritis
Bernard P Leung, Naveed Sattar, Anne Crilly, et al.
Annals of the Rheumatic Diseases
|
February 21, 2014
Ustekinumab, an anti-IL-12/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, placebo-controlled PSUMMIT-1 and PSUMMIT-2 trials
Arthur Kavanaugh, Christopher Ritchlin, Proton Rahman, et al.
Arthritis Research & Therapy
|
May 4, 2019
Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data
A Deodhar, P J Mease, I B McInnes, et al.
Journal of Clinical Periodontology
|
August 2, 2013
Influence of periodontal disease, Porphyromonas gingivalis and cigarette smoking on systemic anti-citrullinated peptide antibody titres
David F Lappin, Danae Apatzidou, Anne-Marie Quirke, et al.
Annals of the Rheumatic Diseases
|
April 22, 2014
Clinical efficacy, radiographic and safety findings through 5 years of subcutaneous golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of a randomised, placebo-controlled trial (the GO-REVEAL study)
Arthur Kavanaugh, Iain B McInnes, Philip Mease, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy
|
August 21, 2017
MicroRNA29a Treatment Improves Early Tendon Injury
Ashlee E Watts, Neal L Millar, Josh Platt, et al.
Page
of 54